<DOC>
	<DOCNO>NCT02428218</DOCNO>
	<brief_summary>The primary objective study assess efficacy oral BG00012 compare placebo pediatric subject relapsing-remitting multiple sclerosis ( RRMS ) . The secondary objective study evaluate safety tolerability BG00012 compare effect BG00012 placebo additional clinical radiological measure disease activity .</brief_summary>
	<brief_title>Placebo-Controlled Study Efficacy Safety BG00012 Pediatric Subjects With Relapsing-Remitting Multiple Sclerosis ( RRMS )</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis , Relapsing-Remitting</mesh_term>
	<mesh_term>Dimethyl Fumarate</mesh_term>
	<criteria>Key Informed consent assent appropriate Must body weight ≥30 kg Must diagnosis RRMS define revise consensus definition pediatric multiple sclerosis ( MS ) Must ambulatory convert Krutzke Baseline Expanded Disability Status Scale ( EDSS ) score 0 5.0 , inclusive Key Primary progressive , secondary progressive , progressive relapse MS. History disorder mimic MS , demyelinate disorder ( e.g. , acute disseminate encephalomyelitis ) , systemic autoimmune disorder ( e.g. , Sjögren disease lupus erythematosus ) , metabolic disorder ( e.g. , dystrophy ) , infectious disorder . History severe allergic anaphylactic reaction , know drug hypersensitivity dimethyl fumarate ( DMF ) fumaric acid ester . Prior treatment follow medication within 12 month prior randomization : mitoxantrone , cyclophosphamide , rituximab . Prior treatment follow medication procedure within 6 month prior randomization : fingolimod , teriflunomide , natalizumab , cyclosporine , azathioprine , methotrexate , mycophenolate mofetil , laquinimod , intravenous ( IV ) immunoglobulin , plasmapheresis cytapheresis . NOTE : Other protocol define inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>10 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Randomized</keyword>
	<keyword>Ages 10-17</keyword>
	<keyword>Pediatrics</keyword>
	<keyword>Placebo control</keyword>
	<keyword>Relapse-Remitting</keyword>
	<keyword>Multiple Sclerosis</keyword>
	<keyword>Safety</keyword>
	<keyword>Efficacy</keyword>
	<keyword>BG00012</keyword>
</DOC>